EVO Stock Analysis: Buy, Sell, or Hold?
EVO - Evotec SE American Depositary Shares
$1.91
-0.06 (-3.05%)
âŧ
5d:
-1.04%
30d:
-1.04%
90d:
-37.79%
WAIT
LOW Confidence
Analysis Updated: Aug 28, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When EVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: EVO is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: EVO is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: EVO is currently trading at $1.91, which is considered slightly low relative to its 30-day fair value range of $1.90 to $2.03. From a valuation perspective, the stock is trading at a discount (Forward PE: -5.1) compared to its historical average (45.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, EVO is in a strong downtrend. The price is currently testing key support at $1.87. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: The stock scores a mixed 52/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $3.85 (+101.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EVO is in a strong downtrend. The price is currently testing key support at $1.87. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: The stock scores a mixed 52/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $3.85 (+101.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.90 -
$2.03
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (52/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.0%)
- BULLISH: Trading 101.6% below Wall St target ($3.85)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 46/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.90 -
$2.03
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.87
Resistance Level
$1.98
Current Trend
Strong Downtrend
Technical data as of
Aug 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.09
Wall Street Target
$3.85
(+101.6%)
Revenue Growth (YoY)
-16.2%
Profit Margin
-27.5%
PE vs Historical
-5.1 vs 45.3
CHEAP
Share & Embed Analysis
Last updated: August 29, 2026 9:21 PM ET
Data refreshes hourly during market hours. Next update: 10:21 PM
Data refreshes hourly during market hours. Next update: 10:21 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 75 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 47 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 49 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 64 BUY |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 48 HOLD |
